NCT03879694View on ClinicalTrials.gov

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

February 15, 2025

Study Completion Date

March 14, 2025

Conditions
Lung Atypical Carcinoid TumorLung Typical Carcinoid TumorMetastatic Pancreatic Neuroendocrine Tumor
Interventions
BIOLOGICAL

Incomplete Freund's Adjuvant

Given SC

DRUG

Octreotide Acetate

Given IM

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

SVN53-67/M57-KLH Peptide Vaccine

Given SC

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

NeuroEndocrine Tumor Research Foundation (NETRF)

UNKNOWN

lead

Roswell Park Cancer Institute

OTHER

NCT03879694 - Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter